BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Truvada (Emtricitabine/tenofovir disoproxil fumarate) readouts
  · AssetMemo
X-WR-CALDESC:Upcoming readouts of Truvada (Emtricitabine/tenofovir disoprox
 il fumarate)\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07584122-970@assetmemo.bio
DTSTAMP:20261121T010027Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Truvada (Emtricitabine/tenofovir disoproxil fumarate): Phase na rea
 dout est. (NCT07584122)
DESCRIPTION:Truvada (Emtricitabine/tenofovir disoproxil fumarate)\, phase n
 a\, HIV.\nStudy: Improving Access to PrEP (HIV Prevention Medication) for 
 People in Underserved Areas of Rio de Janeiro\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/emt
 ricitabine-tenofovir-disoproxil-fumarate#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07584122
URL:https://assetmemo.bio/drug/emtricitabine-tenofovir-disoproxil-fumarate#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02656511-970@assetmemo.bio
DTSTAMP:20261121T010027Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Truvada (Emtricitabine/tenofovir disoproxil fumarate): Phase 4 read
 out est. (NCT02656511)
DESCRIPTION:Truvada (Emtricitabine/tenofovir disoproxil fumarate)\, phase 4
 \, HIV.\nStudy: Immediate Initiation of Antiretroviral Therapy During "Hyp
 eracute" HIV Infection\nEstimated primary completion: May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/emtricitabine-tenofovir-disopro
 xil-fumarate#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT02656511
URL:https://assetmemo.bio/drug/emtricitabine-tenofovir-disoproxil-fumarate#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901101-970@assetmemo.bio
DTSTAMP:20261121T010027Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Truvada (Emtricitabine/tenofovir disoproxil fumarate): Phase 4 read
 out est. (NCT07901101)
DESCRIPTION:Truvada (Emtricitabine/tenofovir disoproxil fumarate)\, phase 4
 \, HIV.\nStudy: Starting HIV Prevention Medicine (PrEP) During an Emergenc
 y Department Visit With a Peer Navigator\nEstimated primary completion: Ma
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/emtricitabine
 -tenofovir-disoproxil-fumarate#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07901101
URL:https://assetmemo.bio/drug/emtricitabine-tenofovir-disoproxil-fumarate#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05957913-970@assetmemo.bio
DTSTAMP:20261121T010027Z
DTSTART;VALUE=DATE:20270604
DTEND;VALUE=DATE:20270605
SUMMARY:Truvada (Emtricitabine/tenofovir disoproxil fumarate): Phase 2 read
 out est. (NCT05957913)
DESCRIPTION:Truvada (Emtricitabine/tenofovir disoproxil fumarate)\, phase 2
 .\nStudy: Effects of Antiviral Therapies on Epstein-Barr Virus Replication
 \nEstimated primary completion: 4 June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/emtricitabine-tenofovir-disoproxil-fumarate#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05957913
URL:https://assetmemo.bio/drug/emtricitabine-tenofovir-disoproxil-fumarate#
 upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
